GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » The Cooper Companies Inc (STU:CP60) » Definitions » Cash Flow from Financing

The Cooper (STU:CP60) Cash Flow from Financing : €97 Mil (TTM As of Apr. 2024)


View and export this data going back to 1983. Start your Free Trial

What is The Cooper Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the three months ended in Apr. 2024, The Cooper paid €0 Mil more to buy back shares than it received from issuing new shares. It spent €54 Mil paying down its debt. It paid €0 Mil more to buy back preferred shares than it received from issuing preferred shares. It received €0 Mil from paying cash dividends to shareholders. It received €0 Mil on other financial activities. In all, The Cooper spent €53 Mil on financial activities for the three months ended in Apr. 2024.


The Cooper Cash Flow from Financing Historical Data

The historical data trend for The Cooper's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

The Cooper Cash Flow from Financing Chart

The Cooper Annual Data
Trend Oct14 Oct15 Oct16 Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23
Cash Flow from Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only -317.67 -81.18 -268.43 1,211.61 -164.68

The Cooper Quarterly Data
Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24
Cash Flow from Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -42.68 -38.87 -6.16 194.89 -53.22

The Cooper Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

The Cooper's Cash from Financing for the fiscal year that ended in Oct. 2023 is calculated as:

The Cooper's Cash from Financing for the quarter that ended in Apr. 2024 is:


Cash Flow from Financing for the trailing twelve months (TTM) ended in Apr. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €97 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


The Cooper  (STU:CP60) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

The Cooper's issuance of stock for the three months ended in Apr. 2024 was €0 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

The Cooper's repurchase of stock for the three months ended in Apr. 2024 was €0 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

The Cooper's net issuance of debt for the three months ended in Apr. 2024 was €-54 Mil. The Cooper spent €54 Mil paying down its debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

The Cooper's net issuance of preferred for the three months ended in Apr. 2024 was €0 Mil. The Cooper paid €0 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

The Cooper's cash flow for dividends for the three months ended in Apr. 2024 was €0 Mil. The Cooper received €0 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

The Cooper's other financing for the three months ended in Apr. 2024 was €0 Mil. The Cooper received €0 Mil on other financial activities.


The Cooper Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of The Cooper's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


The Cooper (STU:CP60) Business Description

Traded in Other Exchanges
Address
6101 Bollinger Canyon Road, Suite 500, San Ramon, CA, USA, 94583
The Cooper Companies is one of the largest eye care companies in the U.S. It operates in two segments: CooperVision and CooperSurgical. CooperVision is a pure-play contact lens business and is composed of a suite of spherical, multifocal, and toric contact lenses. The company also has one of the most comprehensive specialty lens portfolios in the world. With brands including Proclear, Biofinity, MyDay, and clariti, Cooper controls roughly a quarter of the U.S. contact lens market. CooperSurgical, founded in 1990, is made up of equipment related to reproductive care, fertility, and women's care. Cooper has the broadest medical device coverage of the entire IVF cycle. It also has Paragard, the only hormone-free IUD in the U.S., and controls 17% of the U.S. IUD market.

The Cooper (STU:CP60) Headlines

No Headlines